Clinical Trial

A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this study is to evaluate the study drug velzatinib (GSK6042981 / IDRX-42) to see whether velzatinib can shrink or control tumors and is safe and tolerated in Japan participants with gastrointestinal tumors (GIST) who progressed or were intolerant to standard therapies.
Trial Details
NCT Number NCT07689201
Lead Sponsor GlaxoSmithKline
Conditions Gastrointestinal Neoplasms
Enrollment 24 participants
Start Date 2026-08-31
Primary Completion 2027-12-13 (estimated)
Study Completion 2029-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-08